Asthma and Allergy Incidence Drive Leukotriene Modifiers Market to Grow from $21.04B in 2023 to $28.48B by 2028 at 6.3% CAGR, New Report Reveals

The new report published by The Business Research Company, titled "Leukotriene Modifiers Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the leukotriene modifiers market size has grown strongly in recent years. It will grow from $21.04 billion in 2023 to $22.33 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The leukotriene modifiers market size is expected to see strong growth in the next few years. It will grow to $28.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16109&type=smp

The Rising Incidence Of Asthma And Allergic Conditions Drives Growth In The Leukotriene Modifier Market
The rising incidence of asthma and allergic conditions is expected to propel the growth of the leukotriene modifier market going forward. Asthma and allergic conditions refer to a group of disorders characterized by hypersensitivity reactions of the immune system to various allergens, resulting in inflammation and other symptoms. The increasing incidence of asthma and allergic conditions can be attributed to increased exposure to pollutants, rising temperatures, changing weather patterns, and higher population density. Leukotriene modifiers help manage and alleviate symptoms of asthma and allergic conditions while also improving overall respiratory function, reducing inflammation, and providing a safer and more effective treatment option for patients with chronic respiratory issues. For instance, in May 2024, according to the data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, a rising incidence of asthma and allergic conditions is driving the leukotriene modifier market.

Expansion Of Leukotriene Modifiers Market With Generic And Extended-Release Formulations Boosts Asthma Management
Major companies operating in the leukotriene modifier market are focusing on developing generic formulations, such as extended-release (ER) tablets, to expand their portfolios and cater to the growing demand for more convenient and effective treatments. Generic extended-release (ER) tablets are pharmaceutical formulations of medications designed to release their active ingredients gradually over an extended period, typically offering convenience and improved dosing schedules compared to immediate-release formulations. For instance, in April 2023, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, added Zileuton ER Tablets to its portfolio. These tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children aged 12 years and older. The tablets are not intended for the reversal of bronchospasm in acute asthma attacks but can be continued during acute exacerbations of asthma. Zileuton ER Tablets are available in 600 mg strength in 120-count bottles.

The leukotriene modifiers market covered in this report is segmented -
1) By Drug Type: Montelukast, Zafirlukast, Zileuton ER, Zileuton
2) By Form: Tablets, Chewable Tablets, Oral Granules
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16109&type=discount

Major companies operating in the leukotriene modifiers market are Merck And Co., Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Chiesi Farmaceutici S.p.A., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Starallergens Greer Ltd, Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience, Annett Company Inc.

Contents of the report:
1. Executive Summary
2. Leukotriene Modifiers Market Report Structure
3. Leukotriene Modifiers Market Trends And Strategies
4. Leukotriene Modifiers Market - Macro Economic Scenario
5. Leukotriene Modifiers Market Size And Growth
…..
27. Leukotriene Modifiers Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/leukotriene-modifiers-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.